Cargando…

The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan

Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei-Chang, Lin, Sheng-Hao, Hang, Liang-Wen, Lin, Ching-Hsiung, Hsu, Jeng-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604569/
https://www.ncbi.nlm.nih.gov/pubmed/36294532
http://dx.doi.org/10.3390/jcm11206210
_version_ 1784817846978609152
author Huang, Wei-Chang
Lin, Sheng-Hao
Hang, Liang-Wen
Lin, Ching-Hsiung
Hsu, Jeng-Yuan
author_facet Huang, Wei-Chang
Lin, Sheng-Hao
Hang, Liang-Wen
Lin, Ching-Hsiung
Hsu, Jeng-Yuan
author_sort Huang, Wei-Chang
collection PubMed
description Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-related quality of life and its safety in patients with COPD in a routine clinical care setting. This multi-center, prospective, six-month observational study recruited patients diagnosed with COPD and treated with GLY at three medical centers in central Taiwan. The full analysis set (n = 102) had a significant improvement in the Clinical COPD Questionnaire total (mean ± SD = −0.39 ± 0.90, p = 0.002), symptoms (mean ± SD = −0.61 ± 0.90, p < 0.001) and mental state scores (mean ± SD = −0.54 ± 1.72, p = 0.021) but not the functional state score (mean ± SD = −0.10 ± 1.15, p = 0.529). During the observational period, 58 patients (52.73%) experienced adverse events; only one adverse event (dizziness) was suspected to be related to the study drug. Three patients (2.73%) discontinued the study and GLY treatment because of an adverse event. One patient (0.91%) died during the study period because of a cerebral infarction, which was judged to be not associated with GLY treatment. In conclusion, GLY could be effective in improving the health status and is safe for patients with COPD in a real-life setting.
format Online
Article
Text
id pubmed-9604569
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96045692022-10-27 The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan Huang, Wei-Chang Lin, Sheng-Hao Hang, Liang-Wen Lin, Ching-Hsiung Hsu, Jeng-Yuan J Clin Med Article Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-related quality of life and its safety in patients with COPD in a routine clinical care setting. This multi-center, prospective, six-month observational study recruited patients diagnosed with COPD and treated with GLY at three medical centers in central Taiwan. The full analysis set (n = 102) had a significant improvement in the Clinical COPD Questionnaire total (mean ± SD = −0.39 ± 0.90, p = 0.002), symptoms (mean ± SD = −0.61 ± 0.90, p < 0.001) and mental state scores (mean ± SD = −0.54 ± 1.72, p = 0.021) but not the functional state score (mean ± SD = −0.10 ± 1.15, p = 0.529). During the observational period, 58 patients (52.73%) experienced adverse events; only one adverse event (dizziness) was suspected to be related to the study drug. Three patients (2.73%) discontinued the study and GLY treatment because of an adverse event. One patient (0.91%) died during the study period because of a cerebral infarction, which was judged to be not associated with GLY treatment. In conclusion, GLY could be effective in improving the health status and is safe for patients with COPD in a real-life setting. MDPI 2022-10-21 /pmc/articles/PMC9604569/ /pubmed/36294532 http://dx.doi.org/10.3390/jcm11206210 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Wei-Chang
Lin, Sheng-Hao
Hang, Liang-Wen
Lin, Ching-Hsiung
Hsu, Jeng-Yuan
The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title_full The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title_fullStr The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title_full_unstemmed The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title_short The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
title_sort effectiveness and tolerability of glycopyrronium for patients with chronic obstructive pulmonary disease in a clinical setting: glare-taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604569/
https://www.ncbi.nlm.nih.gov/pubmed/36294532
http://dx.doi.org/10.3390/jcm11206210
work_keys_str_mv AT huangweichang theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT linshenghao theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT hangliangwen theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT linchinghsiung theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT hsujengyuan theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT huangweichang effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT linshenghao effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT hangliangwen effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT linchinghsiung effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan
AT hsujengyuan effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan